The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTFB.L Regulatory News (MTFB)

  • There is currently no data for MTFB

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Exercise of Warrants

15 May 2020 07:00

RNS Number : 9759M
Motif Bio PLC
15 May 2020
 

 

Motif Bio plc

("Motif Bio" or the "Company")

 

Exercise of Warrants

 

Motif Bio plc (AIM: MTFB), which has been reclassified as an AIM Rule 15 cash shell, announces that it has received notification from a warrant holder to exercise warrants representing 7,142,857 ordinary shares of 0.01p each ("Ordinary Shares") in the Company for total consideration of £48,571.43. The exercise price of all warrants was 0.68p per warrant.

 

Application has been made for the 7,142,857 new Ordinary Shares to be admitted to trading on AIM ("Admission"), which is expected to occur at 8.00 a.m. on 20 May 2020. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares. The Company does not hold any Ordinary Shares in treasury.

 

Following Admission, and further to the announcement made on 5 May 2020, and for the purposes of the Disclosure Guidance and Transparency Rules, the Company's total issued share capital will consist of 654,991,023 Ordinary Shares. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the issued share capital of the Company.

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

 

For further information please contact:

 

 

Motif Bio plc

 

ir@motifbio.com

Jonathan Gold (President and Chief Business Officer)

 

 

 

SP Angel Corporate Finance LLP (NOMAD & BROKER)

+44 (0)20 3470 0470

David Hignell/Caroline Rowe (Corporate Finance)

 

Vadim Alexandre/Abigail Wayne (Sales & Broking)

 

 

 

Walbrook PR Ltd. (UK FINANCIAL PR & IR)

+44 (0)20 7933 8780

Paul McManus/ Lianne Cawthorne

motifbio@walbrookpr.com

 

 

Forward-Looking Statements

When used in this Press Release, the words or phrases "intends," "anticipates," "expected to be" or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties including, but not limited to, changes in economic conditions in the Company's market area, changes in policies by regulatory agencies, fluctuations in interest rates, competition that could cause actual results to differ materially from historical earnings and those presently anticipated or projected, and other risks described in the Company's filings with the Securities and Exchange Commission. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. The Company advises readers that the factors listed above could affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed with respect to future periods in any current statements. The Company does not undertake, and specifically disclaims any obligation, to publicly release the result of any revision which may be made to any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
IOESFEFMLESSEFI
Date   Source Headline
17th Apr 20187:00 amRNSPosting of UK Annual Report and Notice of AGM
11th Apr 20182:30 pmRNSIclaprim Abstracts for ECCMID 2018 Now Online
10th Apr 20187:00 amRNSFiscal Year 2017 Results
3rd Apr 20183:29 pmRNSHolding(s) in Company
3rd Apr 20187:00 amRNSInitiation of NDA Rolling Submission for Iclaprim
20th Mar 20187:00 amRNSMotif Bio Update on NDA Submission for Iclaprim
19th Mar 20187:00 amRNSMotif Bio to present at upcoming conferences
13th Mar 20183:55 pmRNSChange of Registered Office
7th Mar 201812:29 pmRNSExercise of Warrants
1st Mar 20187:00 amRNSGrant of share options to senior management
21st Feb 20187:00 amRNSMotif Bio to Present Iclaprim Data at ECCMID 2018
19th Feb 201812:53 pmRNSExercise of Warrants
2nd Feb 20183:00 pmRNSAppointment of Interim Chief Financial Officer
29th Jan 201812:07 pmRNSSecond Price Monitoring Extn
29th Jan 201812:02 pmRNSPrice Monitoring Extension
19th Jan 20187:00 amRNSFiling of U.S. Shelf Registration
16th Jan 20187:00 amRNSMotif Bio Receives Award from CF Foundation
12th Jan 20183:12 pmRNSHolding(s) in Company
11th Jan 20183:07 pmRNSHolding(s) in Company
8th Jan 20183:23 pmRNSExercise of Warrants
5th Jan 20187:00 amRNSMotif Bio to participate in panel discussion
22nd Dec 20177:01 amRNSNotes statement from Amphion Innovations
21st Dec 20171:00 pmRNSREVIVE-1 additional results published
14th Dec 20177:00 amRNSFiling of SEC Form F-3
28th Nov 20176:24 pmRNSHolding(s) in Company
17th Nov 20177:00 amRNSExercise of Warrants
17th Nov 20177:00 amRNSHolding(s) in Company
15th Nov 20177:00 amRNSSecures up to US$20 million debt financing
9th Nov 20172:40 pmRNSExercise of Warrants
6th Nov 201712:29 pmRNSHolding(s) in Company
18th Oct 20177:00 amRNSHolding(s) in Company
6th Oct 20171:20 pmRNSHolding(s) in Company
6th Oct 20177:00 amRNSNew Pre-Clinical Data for Iclaprim at IDWeek 2017
5th Oct 20179:57 amRNSHolding(s) in Company
4th Oct 20177:00 amRNSPositive Topline Results in Phase Three Study
29th Sep 20177:00 amRNSHalf-year Report
25th Sep 20177:01 amRNSHolding(s) in Company
15th Sep 20172:07 pmRNSiclaprim granted Orphan Drug Designation by US FDA
8th Sep 20171:00 pmRNSHost Investor and Analyst Event on September 20
31st Aug 20171:00 pmRNSCompany to present at conferences in September
30th Aug 20177:00 amRNSHolding(s) in Company
9th Aug 20177:00 amRNSREVIVE 2 Trial Last Patient Treated
18th Jul 20177:00 amRNSAmendment to Amphion Consultancy Agreement
6th Jul 20177:00 amRNSPRESENTING THREE POSTERS ON ICLAPRIM AT ID WEEK
28th Jun 201712:41 pmRNSExercise of warrants
27th Jun 20177:00 amRNSHolding(s) in Company
22nd Jun 20173:20 pmRNSResult of General Meeting
22nd Jun 20177:00 amRNSPresents at ID Week 2017
15th Jun 20175:42 pmRNSResults of Annual General Meeting
14th Jun 20177:00 amRNSPresentation at BIO International Convention

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.